

## A Study on Effective Diabetic Retinopathy Using Deep Learning Approach

Mr. Kundan. B<sup>\*1</sup>, Dr. S. Pushpa<sup>2</sup>

<sup>1</sup>Research Scholar, Department of CSE, St. Peter's Institute of Higher Education and Research, Avadi, Chennai, Tamil Nadu, India.

<sup>2</sup>Professor, Department of CSE, St. Peter's Institute of Higher Education and Research, Avadi, Chennai, Tamil Nadu, India.

**Email ID:** kbaws2021@gmail.com<sup>1</sup>, pushpasangar961@gmail.com<sup>2</sup>

**\*ORCID ID:** <https://orcid.org/0009-0007-9511-1983>

### Abstract

The goal of the project is to apply machine learning and deep learning approaches to diagnose diabetic retinopathy (DR). Diabetic retinopathy (DR) is one of the most notable and important microvascular consequences of diabetes mellitus. This degenerative disorder affects the retina and might cause blindness if therapy is not received in a timely manner. By having a complete grasp of the route physiology, acquiring a prompt diagnosis, and employing effective management approaches, the effects on the affected individuals can be minimised. The IDRID dataset and AGAR300 Dataset retinal pictures are used to identify the DR utilising a variety of manual engineering and end-to-end learning-based techniques. Early disease management depends on the identification of the mild stage. Similarity measurements are important in many data mining techniques. To enable the application of Haar Wavelet Transform algorithms (HWT) on non-standard databases, such as databases of financial time series, their similarity measure must be devised. The work focuses on a simple yet efficient approach that may be used to rapidly determine the degree of similarity between time series stored in large datasets. The goal of this work is to employ end-to-end deep ensemble networks to identify every stage of drug resistance. The results demonstrate that the suggested strategy works better than cutting-edge techniques. Pre-processing methods like as data augmentation, which increases the amount of training instances, and data normalisation, which accurately predicts classification, are necessary to provide the best mass image dataset for training models. Thus, the most recent CNN models (AlexNet, VggNet, GoogleNet, and ResNet) might be trained to identify the minute variations among the picture classes for DR Detection. Adopting hyper-parameter tuning with transfer learning techniques has shown experimental findings to be more accurate than non-transferring learning approaches in classifying DR images. It operates on the basis of the Orthonormal decomposition of the time series into the Haar basis. We demonstrate that this technique can produce estimates of the local slope of the time series across a variety of multi-resolution stages. The Haar representation and similar representations generated from it are suitable for direct comparisons, such evaluating the correlation product. We show that there is a strong correlation between the distance between such representations and the subjective sense of likeness between the time series. We examine the trade logs to verify the reliability of the subjective standards and discover robust associations.

**Keywords:** Diabetic Retinopathy (DR), IDRID, Haar-Wavelet Transform (HWT), Time Series, Sign Representation, Convolutional Neural Networks (CNN).

### 1. Introduction

Blindness has several important causes, one of which being diabetic retinopathy (1DR). A diabetic patient's retinal blood vessels are damaged by DR. Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR) were the

two main forms of DR [9]. The early phases of the DR were referred to as NPDR, and they were further separated into three levels: mild, moderate, and severe. One Microaneurysma (MA), a tiny red dot that is round in shape and located at the terminal of

blood vessels, is present in the moderate stage. The MAs rip into deeper layers and create a flame-shaped haemorrhage in the retina at the moderate stage. At each of the four quadrants, there are over 20 intrareticular haemorrhages at the severe stage. There is also noticeable intrareticular microvascular anomalies and distinct venous bleeding [10]. PDR is the more advanced stage of DR that causes neovascularization, which is the spontaneous growth of new blood vessels on the inner surface of the retina in the form of functioning microvascular networks [11]. By 2025, there were projected to be 592 million DR sufferers worldwide, up from 382 million [12]. Individuals with diabetes are vulnerable to neurovascular issues that may lead to diabetic retinopathy and/or diabetic macular edema (DME). Researchers found that 25% of individuals had non-proliferative diabetic retinopathy (NPDR) five years after receiving a diabetes diagnosis, 60% had it 10 years later, and 80% had it fifteen years later [13-16]. As per the findings of these studies, the prevalence of proliferative diabetic retinopathy (PDR) varied between 2.5% and 15.5% among individuals diagnosed with diabetes mellitus for a duration of fifteen years or more. Optometrists are the only medical professionals who may noninvasively assess systemic disease-related physical damage to blood vessels in the human body. This underlines the significance of closely monitoring all diabetic patients and collaborating with endocrinologists or primary care physicians (PCPs) to assist in their management [17-19]. Patients diagnosed with type 1 diabetes are advised by optometrists to get a thorough dilated eye examination no later than five years from the commencement of the disease. Patients with type 2 diabetes should have a comprehensive dilated eye examination both at the time of diagnosis and annually thereafter. Women who have previously been diagnosed with type 1 or type 2 diabetes, either before becoming pregnant or during the first trimester of pregnancy, should have a comprehensive dilated eye examination [20-22].

### **Study is about?**

In most cases, patients with NPDR have different-sized hemorrhages, venous looping or beading, intraretinal microvascular abnormalities (IRMAs), hard exudates, soft exudates (cotton wool patches),

and microaneurysms (MAs). Loss of intramural pericytes has damaged the retinal capillaries, resulting in the formation of MAs, which are saccular outpouchings [23-27]. Hemorrhages could occur through capillary walls progressively deteriorating and breaking up. IRMAs are either preexisting vessels with proliferation endothelial cells traveling through nonperfusion regions or new blood vessels formation within the retina [28]. The presence of IRMA signals ischemia and serves as a trigger for neovascularization. Severe retinal hypoxia is the cause of venous looping and beading, which represent a higher risk of neovascularization progression. When you have a diabetic patient in your chair, it is critical to learn as much as you can about their health [29].

### **2. Problem Definition**

The most common impairment among living people was blindness, and diabetes is one of the main causes of blindness. The DR detection systems have longer execution times in addition to increased implementation costs. Thus, methods based on deep learning are created to address these problems. AlexNet, VggNet, GoogleNet, and ResNet are used by CNN [1] for DR image categorization. In this approach, the variability in morphological and other picture parameters, such as look, colour, and texture, was enhanced for recognising genuine haemorrhages of candidates. The accuracy of VggNet's model was good in comparison to other models. However, it performs poorly in terms of classification accuracy and lacks fundus images, which causes problems with data augmentation and normalisation. CNN [2] lowers the likelihood of vision loss. It is also a very time- and money-efficient procedure. There was no human expert involved in the adjudication of the labels used in this training and validation set, hence they were not interpretable. DCNN [3] provides high-performance, low-latency interference medical image detection and segmentation. Additionally, it makes advantage of semantic segmentation of fundus pictures, which may improve NPDR's accuracy and efficiency. As a result, the training process takes longer, there are more imbalances, and the resulting model is more complicated. CNN [4] has superior specificity and sensitivity and can identify all stages of DR with excellent detection accuracy. However,

for the last step of decision-making, qualified specialists are required. More reliable results in DR related feature recognition and DR severity diagnosis are obtained with hierarchical multi-task learning [5]. However, it is unable to encode the changes in light, rotation, and scale. DLSBVM [6] reduces the mistakes in incorrectly identifying vessel pixels from non-vessel images by utilising several layers. Furthermore, it enhances the image's contrast and eliminates noise from photos taken under various lighting conditions. However, because the margins did not emerge due to the difference in picture intensity between the vessel and backdrop, the best blood vessels were overlooked. Higher convergence rates are provided by DRISTI [7], which may increase the screening rate for DR patients. However, the dataset they utilised for this experiment was not balanced for the distribution of classes, and the system's implementation cost was relatively expensive. Back-propagation neural network architecture and a poorly supervised learning technique were used in the creation of CNN [8], which had certain advantages over automatic DR detection. The maintenance cost was expensive since it makes use of many filter algorithms and network settings. The recently established technique of retinopathy detection overcomes these obstacles.


### **Stage 1: MILD Non-Proliferative diabetic retinopathy (NPDR)**

These patients show no other abnormalities in the picture below, but they do have at least one MA. Since results are frequently subtle, careful examination and observation are crucial. Every year, these patients ought to undergo a dilated eye exam. And there is a chance of five percent that mild NPDR will turn into PDR. A patient should be referred to a PCP for further examination if they are diagnosed with one or more MAs in their eyes and are suspected of being diagnosed with diabetes. You can keep an eye on patients' disease progression by recording tiny discoveries and specifying their precise locations. If available, use fundus images to facilitate comparisons in the future. Unless you have verified a diagnosis of DME or are concerned about a patient with mild NPDR, there is no need to refer them to a retina expert. Patients should be informed of the findings and their potential consequences,

particularly if they are newly diagnosed with diabetes. It is crucial to explain to them that MAs signify early end organ damage from their condition. Motivate them to keep an eye on their nutrition and blood sugar levels. Provide the patient's PCP and/or endocrinologist a thorough report so they are aware of the results and can use it to help them decide on a course of treatment.

### **Stage 2: Moderate NPDR**

Every six to eight months, patients with moderate NPDR should be examined. Within a year, there is a 12% to 27% chance that they will get proliferative diabetic retinopathy (PDR). In cases when you suspect DME, you may choose to obtain macular OCT images. Fundus photography is advised for these individuals. Unless you have proven DME or you feel OCT imaging is necessary but cannot obtain this technology, these individuals do not need to be referred to a retina expert. Informing these patients about the results and their implications for the course of the disease is crucial once more.



**Figure 1 Patient with Moderate NPDR**

It can be essential to send patients back to their PCP or endocrinologist earlier than planned so they can discuss treatment modifications, depending on their most recent blood sugar management and the results of their most recent diabetic examination with those professionals (Figure 1).

### **Stage 3: Severe NPDR**

These patients exhibit venous beading in two or more quadrants, an IRMA in one or more quadrants, and intraretinal hemorrhages. The 4:2:1 rule refers to this. Neovascularization, which would suggest PDR, must not be present in these data.



**Figure 2 Severe NPDR**

Macular OCT and fluorescein angiography should be used in conjunction to follow patients with severe NPDR to identify any early neovascularization or DME. Patients should be followed up with dilated fundus examinations every three to four months, and referrals to retina specialists are advised. To monitor these individuals, you might be able to collaborate with a retina specialist by scheduling alternating consultations. Discussing with patients who have severe NPDR the significance of blood sugar control and close observation is vital, since they have a 52% chance of developing PDR within a year. To discuss retinal findings, it is also necessary to contact the patient's PCP or endocrinologist. Currently, these patients are probably having neuropathy elsewhere and are at a significant risk of both permanent visual loss and disease progression (Figure 2).

#### **Stage 4: Proliferative Diabetic Retinopathy**

These patients show evidence of either vitreous/preretinal bleeding or neovascularization of the disc/elsewhere after their NPDR advanced to PDR. For additional testing and treatment, these patients need to be referred right away to a retina expert. Laser panretinal photocoagulation is the typical treatment for peripheral neovascularization. In addition, they frequently receive intravitreal injections of anti-VEGF, which may be administered in addition to PRP. These individuals require monthly follow-up visits with a retina specialist until their illness stabilizes. After that, they might see someone every six to twelve months. Inform the patient's PCP and/or endocrinologist of all results. If the patient's PDR is new, a phone call is necessary.

#### **3. Research Methodology**

One typical consequence of diabetes mellitus is diabetic retinopathy (DR), which results in retinal lesions that impair vision. It can result in blindness if

it is not discovered early. Sadly, there is no cure for DR; therapy just keeps the eyesight intact. Early diagnosis and treatment of DR can greatly lower the risk of visual loss. Unlike computer-aided diagnostic techniques, the manual diagnosis procedure of DR retina fundus photographs by ophthalmologists is time-consuming, costly, and prone to misdiagnosis. Deep learning has emerged as one of the most popular methods recently, showing improved performance in several domains, including medical picture analysis and classification. Therefore, our goal was to create a deep learning-based DR detection method that would use deep learning both in the segmentation and detection stages. First, the conventional web data sources will be used to gather the necessary photos for the identification of DR. After that, the gathered picture will be sent for Swinunet-based blood vessel segmentation. To extract stacked features, for example, the segmented pictures will be fed into the Dilated-Densenet using Resnet. In order to provide promising outcomes over DR detection, the final stage detection will be performed with the assistance of Hierarchical Multi-scale RNN with parameter optimisation. The newly developed Manta Ray Foraging Optimization (MRFO) and Shark Smell Optimization (SSO) algorithm will be used here for maximizing the effectiveness of the developed DR detection approach. The implementation outcome will be analyzed over various DR detection approaches for validating the performance of the developed model.

#### **4. Treatment for DME**

From minor DR to severe proliferative disease, diabetic macular edema (DME) can develop at any stage of retinopathy. Over the previous twenty years, there has been a significant shift in the therapeutic paradigm for individuals with DME. The Early Treatment Diabetic Retinopathy Study (ETDRS) results, which showed that focal laser photocoagulation was superior to observation for clinically significant DME, although a significant proportion of treated patients eventually lost vision, served as the foundation for standard protocol for many years. Currently, intravitreal injections of one or more anti-VEGF medicines constitute the first-line treatment for the majority of DME cases. These drugs have good safety profiles and over time can stabilize

and even improve vision. It is no longer a concern to determine whether DME meets the ETDRS criteria for clinical significance. Nowadays, doctors employ OCT to identify whether edema is center-involving or non-center-involving. Based on this finding and the patient's VA, they then decide what course of treatment to take. For imaging, identification, categorization, and management, OCT is unquestionably the gold standard of therapy, especially for patients whose BCVA is less than 20/20 and who do not have another evident cause of vision loss. Of course, we still perform OCT and view the macula stereoscopically through a dilated pupil.

### Conclusion

Prior until recently, low vision rehabilitation and laser therapy were the only forms of treatment and management that doctors could provide to patients with DME and PDR. The future is now more promising than ever for people with diabetic eye disease thanks to the development of safe and efficient pharmaceutical treatments and the tremendously advancing of technologies like Artificial Intelligence, Machine Learning and Deep learning, that enhance both visual outcomes and quality of life.

### Acknowledgements

The source of the study has been rooted to previous papers, Book chapters and FAAO.

### References

- [1] Cecelia Koetting, OD, FAAO, Referral, Optometric Care and Externship Program Coordinator, Virginia Eye Consultants, Norfolk.
- [2] Bozkaya G, Ozgu E, Karaca B. The association between estimated average glucose levels and fasting plasma glucose levels. *Clinics (Sao Paulo)*. 2010;65(11):1077-1080.
- [3] Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol*. 1984.
- [4] Shaohua Wan, Yan Liang, Yin Zhang, "Deep convolutional neural networks for diabetic retinopathy," *Computers and Electrical Engineering*, vol. 72, pp. 274-282, 2018.
- [5] Gaurav Saxena, Dharendra Kumar Verma, Amit Paraye, Alpna Rajan, Anil Rawat, "Improved and robust deep learning agent for preliminary detection of diabetic retinopathy using public datasets," *Intelligence-Based Medicine*, vol. 3-4, pp. 100022, December 2020.
- [6] L. Qiao, Y. Zhu and H. Zhou, "Diabetic Retinopathy Detection Using Prognosis of Microaneurysm and Early Diagnosis System for Non-Proliferative Diabetic Retinopathy Based on Deep Learning Algorithms," *IEEE Access*, vol. 8, pp. 104292-104302, 2020.
- [7] Sehrish Qummar; Fiaz Gul Khan; Sajid Shah; Ahmad Khan, Shahabuddin Shamshirband, "A Deep Learning Ensemble Approach for Diabetic Retinopathy Detection," *IEEE Access*, vol. 7, pp. 150530-150539, 2019.
- [8] Jiang, Ming, "Multi-view Deep Learning for Diabetic Retinopathy Detection," Master's Programme in ICT Innovation, 2017.
- [9] T. Jemima Jebaseeli, C.Anand Deva Durai, J.Dinesh Peter, "Retinal blood vessel segmentation from diabetic retinopathy images using tandem PCNN model and deep learning based SVM," *Optik*, vol.199, pp. 163328, December 2019.
- [10] Gaurav Kumar, Shraban Chatterjee, Chiranjoy Chattopadhyay, "DRISTI: a hybrid deep neural network for diabetic retinopathy diagnosis," *Signal Image and Video Processing*, 2021.
- [11] Sabyasachi Chakraborty, Gopal Chandra Jana, Divya Kumari & Aleena Swetapadma, "An improved method using supervised learning technique for diabetic retinopathy detection," *International Journal of Information Technology*, vol. 12, pp.473-477, 2020.
- [12] A. B. Aujih, M. I. Shapiai, F. Meriaudeau and T. B. Tang, "EDR-Net: Lightweight Deep Neural Network Architecture for Detecting Referable Diabetic Retinopathy," *IEEE Transactions on Biomedical Circuits and Systems*, vol. 16, no. 3, pp. 467-478, June 2022.
- [13] Y. Niu, L. Gu, Y. Zhao and F. Lu, "Explainable Diabetic Retinopathy Detection and Retinal Image Generation," *IEEE Journal of Biomedical and Health Informatics*, vol. 26, no. 1, pp. 44-55, Jan. 2022.
- [14] Z. Khan et al., "Diabetic Retinopathy Detection Using VGG-NIN a Deep Learning Architecture," *IEEE Access*, vol. 9, pp. 61408-61416, 2021.
- [15] T. Araújo et al., "Data Augmentation for Improving Proliferative Diabetic Retinopathy Detection in Eye Fundus Images," *IEEE Access*, vol. 8, pp. 182462-182474, 2020.

- [16] M. Mateen, J. Wen, M. Hassan, N. Nasrullah, S. Sun and S. Hayat, "Automatic Detection of Diabetic Retinopathy: A Review on Datasets, Methods and Evaluation Metrics," *IEEE Access*, vol. 8, pp. 48784-48811, 2020.
- [17] M. M. Farag, M. Fouad and A. T. Abdel-Hamid, "Automatic Severity Classification of Diabetic Retinopathy Based on DenseNet and Convolutional Block Attention Module," *IEEE Access*, vol. 10, pp. 38299-38308, 2022.
- [18] F. Saeed, M. Hussain and H. A. Aboalsamh, "Automatic Diabetic Retinopathy Diagnosis Using Adaptive Fine-Tuned Convolutional Neural Network," *IEEE Access*, vol. 9, pp. 41344-41359, 2021.
- [19] H. Mustafa, S. F. Ali, M. Bilal and M. S. Hanif, "Multi-Stream Deep Neural Network for Diabetic Retinopathy Severity Classification Under a Boosting Framework," *IEEE Access*, vol. 10, pp. 113172-113183, 2022.
- [20] S. H. Abbood, H. N. A. Hamed, M. S. M. Rahim, A. Rehman, T. Saba and S. A. Bahaj, "Hybrid Retinal Image Enhancement Algorithm for Diabetic Retinopathy Diagnostic Using Deep Learning Model," *IEEE Access*, vol. 10, pp. 73079-73086, 2022.
- [21] L. Qiao, Y. Zhu and H. Zhou, "Diabetic Retinopathy Detection Using Prognosis of Microaneurysm and Early Diagnosis System for Non-Proliferative Diabetic Retinopathy Based on Deep Learning Algorithms," *IEEE Access*, vol. 8, pp. 104292-104302, 2020.
- [22] M. Ghazal, S. S. Ali, A. H. Mahmoud, A. M. Shalaby and A. El-Baz, "Accurate Detection of Non-Proliferative Diabetic Retinopathy in Optical Coherence Tomography Images Using Convolutional Neural Networks," *IEEE Access*, vol. 8, pp. 34387-34397, 2020.
- [23] B. Yang, T. Li, H. Xie, Y. Liao and Y. -P. P. Chen, "Classification of Diabetic Retinopathy Severity Based on GCA Attention Mechanism," *IEEE Access*, vol. 10, pp. 2729-2739, 2022.
- [24] K. Aurangzeb, S. Aslam, M. Alhussein, R. A. Naqvi, M. Arsalan and S. I. Haider, "Contrast Enhancement of Fundus Images by Employing Modified PSO for Improving the Performance of Deep Learning Models," *IEEE Access*, vol. 9, pp. 47930-47945, 2021.
- [25] Santiago Toledo-Cortés, Diego H. Useche, Henning Müller, Fabio A. González, "Grading diabetic retinopathy and prostate cancer diagnostic images with deep quantum ordinal regression," *Computers in Biology and Medicine*, vol.145, pp.105472, June 2022.
- [26] Azat Garifullin, Lasse Lensu, Hannu Uusitalo, "Deep Bayesian baseline for segmenting diabetic retinopathy lesions: Advances and challenges," *Computers in Biology and Medicine*, vol.136, pp.104725, September 2021.
- [27] Mr. KUNDAN. B, Dr. S. Pushpa, "Machine Learning Approaches on Health Care Data: A Survey", *IJRAR - International Journal of Research and Analytical Reviews (IJRAR)*, E- ISSN 2348- 1269, P- ISSN 2349-5138, Volume.11, Issue 1, Page No pp.849-854, January 2024.
- [28] Mr. KUNDAN. B, Dr. S. Pushpa, "Machine Learning Techniques Used for Recognizing The Diabetic Retinopathy: A Survey", *IJETMS – International Journal of Engineering Technology and Management Sciences*, Website: [ijetms.in](http://ijetms.in) Issue: 2 Volume No.8 March - April – 2024, ISSN: 2581-4621, <https://ijetms.in/Vol-8-issue-2/Vol-8-Issue-2-13.pdf>,
- [29] Mr. KUNDAN. B, Dr. S. Pushpa, Participated and Presented a paper in the conference of ICFTSEM: conference paper published in *ijetms* paper id:2402012. link: <https://ijetms.in/Vol-8-issue-2/Vol-8-Issue-2-13.pdf>.